Dana-Farber retracts string of studies in data integrity review

A 2006 Science paper co-authored by Dana-Farber president and CEO Laurie Glimcher is the latest in a series of retractions.

April 18, 2024 Check out STAT+

Sponsored By

Craig F. Walker/Globe Staff STAT+ | Dana-Farber retracts string of studies in systematic review of data integrity Dana-Farber CEO Laurie Glimcher, a co-author, requested the retraction from a prominent journal after questions were raised about images. By Angus Chen USDA faulted for disclosing scant information about outbreaks of H5N1 avian flu in cattle With 28 herds in eight states infected with H5N1, scientists are calling on the U.S. to release more data to help them assess the risk. By Helen Branswell STAT+ | 23andme CEO Anne Wojcicki moves to take company private CEO Anne Wojcicki disclosed her plans in a filing with the Securities and Exchange Commission late Wednesday. By Allison DeAngelis Mike Reddy for STAT STAT+ | Microsoft is selling AI in health care, and helping to set its standards. Is that a problem? For some, Microsoft's deep involvement in groups setting standards for the use of AI in health care raises questions about "regulatory capture." By Casey Ross and Brittany Trang STAT+ | Elevance's private equity deal will form $4 billion primary care company Elevance joins a growing list of insurers that have launched similar ventures, including UnitedHealth Group, Humana, and CVS Health. By Tara Bannow Opinion: Former HHS secretaries: Congress should adopt site-neutral payments for health care Site-neutral payments (tying payment to a procedure or service rather than to where care is delivered) will reduce U.S. health care costs. By Alex Azar and Kathleen G. Sebelius Wong Maye-E/AP STAT+ | Animal rights group urges SEC to investigate Charles River over monkey purchases "The company's shareholders... have the right to expect that their company won't mislead them with deceptive statements," PETA maintained. By Ed Silverman STAT+ | Cerevel drug for Parkinson's disease improved symptom control in trial The neuroscience biotech that AbbVie is acquiring said Thursday its drug tavapadon, taken with the drug levodopa, showed positive results. By Elaine Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser